>> caller: my concerns are novo nordisk. >> no, no, no. they had one of wo quarters of the year. we're not going to go there. i suggest you go to merck because novo nordisk had price competition on pretty much every drug it puts out. oh, i see, you had to do it with your right hand. anyway, they're plenty of big reports next week before you get to enjoy your thanksgiving turkey. let's not kid ourselves. if president-elect trump lands a big appointee to this cabinet, that could give the market something to feast on. if he fails, things could get on "mad money" tonight, united continental was once the black sheep of the airlines. with the stock flying higher, is it clear skies after buffett took his stake? then it's been just over a week since trump won the general election. what could the president-elect's policies mean for apple and its shareholders? and with black friday a week away, i'm giving you my retail wrap-up. i suggest you stick withme >> announcer: don't miss a second of "mad money." follow @jimcramer on twitter. have a question? tweet cramer, #madtweets. send jim an e-

novo nordisk is really the poster child here. they're facing both price competition on insulin and public shame for past price increases on the same darn products. if you own these, reposition. what works, then? for starters, i think merck is one of your best bets. here's a company that's gotten a lot of good news lately, anti-cancer franchise, keytruda. merck is now in the lead when it comes to next-generation cancer drugs, particularly after the public setbacks in the bristol-myers competing oncology formulation opdivo. merck rocketed up 6% today on the election results but even after this move, it's only 16.5 times next year's earnings estimates. solid 2.7% dividend yield. that is too cheap. >> buy, buy, buy. >> how about pfizer, pfe? here's a stock that's facing terribly negative sentiment in recent months, but i think the mp with huge free cash flow. granted, pfizer soared 7% today, but the stock is still five points off its highs. it's trading at just 12.3 times next year's earnings estimates. i regard that as very cheap, e

drugmakers like novo nordisk rising today after the trunk victory, removing concerns that clinton would push for price controls. this has risen the most since 2008. interestingly, glaxosmithkline said that pressure on drug prices in the u.s. will continue regardless of who wins the presidency. , is rebounding when ittwo-year low fell through 17 percent. basic resources rising on the assumption that more spending will happen in the infrastructure space, boosting demand for metals and helping mining companies. ramstad,he likes of benefiting from the earlier jump in the gold price. ram gold up as much as 10% earlier. a trump presidency could send boolean to almost $1400 an ounce llion tog to 20 -- bu almost $1400 an ounce according to 20 analysts. defense stocks could win as trump boosts spending on defense. he could increase spending on aircraft, ships, and troops benefiting many of the companies on the ftse 200 aerospace and defense index. julie, what has been the impact? julie: it is curiously muted and the major averages are very little changed with the dow s&ping 43, the data -- the a

in this case, the stoxx 600, you can see novartis, roche, novo nordisk. and swiss names that are waiting on the stoxx 600, which is why you see the ftse, the cac, and the dax gaming while the stoxx 600 falls down. it has those non-core elements on the on -- weighing index. interesting that you are saying the pharmaceuticals dragging down also. novartis wanting to buy celexa. matt: you have some there, but they are not as heavy european wide. the lodget down, year. it is really the swiss and swedish movers that are the drag on the stoxx 600. let's get to the bloomberg business flash with sebastian salek. seb: thanks, matt. cyber security giant symantec is buying identity theft company lifelock. lifelock was being sued. by 45 percent up this year, giving it a market value of almost $2 billion. facebook plans to take on another 500 workers in britain. the move would expand the social network presence in the u.k. by 50%. that is when the company opens a london headquarters next year. we will be talking to the facebook vice president at 9:20 u.k. time. u.k. se

novo nordisk winning a new drug. and astrazeneca has been cleared to resume enrollment in a cancer trial. >> fidelity investments chief will succeed her father as the firm's chair. "wall street journal" kriegt an internal memo. move is effective early next month. >> markets making history ahead of the holidays. dow, s&p, nasdaq and the russell 2000 are rallying to record closing highs. optimism about a possible deal to cut oil production was one of the cat list for that event. joining us now is ed keenan and steven whiting global chief investment strategist. we had tested a couple of counter factuals. i love that, ed, because i love counter factuals because they become narrative of what would have happened. brexit we knew the market would clap. we saw that didn't happen. we saw that the stock market was supposed to go down 10% if trump was elected. that didn't happen. let me saw question on a different counter factual. in your few if hillary clinton was elected president would the markets be where they are now >> pro